ArticleKidney medicine2025
Temporal and Demographic Trends in Biopsy-Proven Kidney Disease Diagnoses in the Southwestern United States, 1993-2022.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spectrum of biopsy-proven kidney diseases in 3514 patients at a single center in Northwest China from 2014 to 2023.Clinical and experimental nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Rationale & Objective: Kidney biopsy is vital to diagnose and manage medical kidney diseases. However, not many large-scale studies for medical kidney disease have been reported worldwide. We describe 30-year temporal and demographic trends in biopsy-proven glomerular and nonglomerular diseases in the Southwestern United States. Study Design: Retrospective single-center cohort study. Setting & Participants: Native kidney biopsy cases referred to the Renal Pathology Service at Cedars-Sinai Medical Center between 1993 and 2022. Predictors: Biopsy era (1993-2002, 2003-2012, and 2013-2022) and demographics (age, sex, and race) were primary and secondary predictors. Outcomes: Relative frequencies (percentages) of 35 widely recognized glomerular/ nonglomerular disease categories are primary outcome. Analytical Approach: Non-numerical and numerical variables were compared using χ Results: In total, 57,613 patients were identified, with a mean age 51.0 (± 19.2) years, 52.2% men, 53.8% White, 19.5% Latino, 11.0% Black, 10.2% Asian, and 5.5% other race. Glomerular disease relative frequency was always higher than nonglomerular disease frequency. Among the glomerular diseases, the relative frequency of diabetic glomerulosclerosis in our cohort was constantly and rapidly increasing, whereas those of other glomerular disease categories were decreasing except for antineutrophil cytoplasmic antibody/pauci-immune glomerulonephritis. However, the decline in the relative frequency of glomerular diseases was much less apparent when diabetic glomerulosclerosis was removed. Among the nonglomerular diseases, acute tubular necrosis was increasing in frequency. These temporal trends were largely preserved in all demographic subgroups, although there were several cross-sectional differences of glomerular disease frequencies within each demographic subgroup. Limitation: Retrospective and observational study design, no patient/kidney outcomes, some missing patients' data, and possible misclassification of disease categorization. Conclusions: To our best knowledge, we provided the largest and latest medical kidney biopsy data, which may provide valuable insights to predict the relative likelihood of a disease diagnosis in a daily medical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.